Compare YUMC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUMC | SNN |
|---|---|---|
| Founded | 1987 | 1856 |
| Country | China | United Kingdom |
| Employees | N/A | 16988 |
| Industry | Restaurants | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 14.3B |
| IPO Year | 2016 | N/A |
| Metric | YUMC | SNN |
|---|---|---|
| Price | $42.68 | $29.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | 2.38% | ★ 2.48% |
| EPS Growth | ★ 7.73 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $11,797,000,000.00 | N/A |
| Revenue This Year | $9.42 | $8.58 |
| Revenue Next Year | $5.86 | $5.60 |
| P/E Ratio | ★ $48.97 | $64.97 |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $41.69 | $28.40 |
| 52 Week High | $58.39 | $38.79 |
| Indicator | YUMC | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 22.84 | 37.43 |
| Support Level | $42.39 | $29.08 |
| Resistance Level | $44.50 | $33.89 |
| Average True Range (ATR) | 0.87 | 0.48 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 1.22 | 13.56 |
Yum China is the largest restaurant operator in China, with over 18,000 locations and USD 12 billion in systemwide sales as of 2025. It generates revenue mainly from its own restaurants and franchise fees. While KFC and Pizza Hut are its flagship brands, Yum China's portfolio also includes Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza. As a trademark licensee of Yum Brands, Yum China pays 3% of KFC and Pizza Hut's systemwide sales to its former parent, from which it spun off in 2016. However, even before the separation, Yum China was granted substantial autonomy, giving its Chinese leadership decision-making authority over menu, supply chain, and marketing-an unusual practice for Western chains at the time.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.